Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 13/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658747 | 0.87 | GPR119 (0.56) | GPR119CTSSRIPK1HRH4HRH3 | |
| SCHEMBL19652224 | 0.82 | GPR119 (0.48) | GPR119CTSSRIPK1HRH4HRH3 | |
| SCHEMBL19652137 | 0.80 | CTSS (0.48) | GPR119CTSSRIPK1AAK1 | |
| SCHEMBL19652109 | 0.78 | GPR119 (0.55) | GPR119RIPK1HRH4HRH3AAK1 | |
| SCHEMBL19652135 | 0.74 | AAK1 (0.39) | GPR119AAK1 | |
| SCHEMBL19652111 | 0.74 | KDM4E (0.51) | — | |
| SCHEMBL19652105 | 0.74 | KDM4E (0.54) | GPR119 | |
| SCHEMBL3485936 | 0.74 | GPR119 (1.00) | GPR119 | |
| SCHEMBL19652108 | 0.73 | TRPV1 (0.46) | GPR119RIPK1AAK1 | |
| SCHEMBL19652130 | 0.73 | ADRB1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | GPR119 988/4885CTSS 2525/4885RIPK1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.